Future of Personalized Medicine

  • Kewal K. Jain


Based on the current progress in biotechnology and molecular medicine, considerable advances and breakthroughs are expected in the second decade of the twenty-first century. These will involve progress towards finding a cure for cancer and making it a chronic manageable disease. Many of the advances will be through application of new technologies such as nanobiotechnology and refinements of cell therapy, particularly the use of stem cells. Automation, robotics and informatics will be partially integrated into clinical medicine. Advances in regenerative medicine and tissue engineering will enable repair and regeneration of damage in CNS and cardiac disorders. The emphasis in treatment of neurological disorders will be on neuroprotection rather than control of symptoms. Management of infectious diseases will improve although unpredictable challenges may arise from emerging viral infections. In the setting of this progress, personalized medicine will be an important part of managing patients. Advances in molecular diagnostics and discovery of biomarkers will facilitate this development. Important advances relevant to personalized medicine will be: Pathomechanism of most of the currently known major diseases will be understood at the molecular level. Genomic, proteomics, metabolic data from various research and commercial sources will be integrated in clinical medicine. Most of the ethical and policy issues about genetic testing will be resolved and it will be a routine for some population groups. Pharmacogenetics will be applied to identify those at risk of adverse drug events from certain drugs. Improvements in targeted drug discovery and increase in pharmacogenomics-based clinical trials. Preventive medicine will be well recognized with acceptance of presymptomatic diagnosis and pre-emptive treatments.


Genetic Testing Personalized Medicine Molecular Diagnostics GWAS Data Genomic Medicine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Church GM (2006) Genomes for all. Scientific American 294:33–40.Google Scholar
  2. Goldstein DB (2009) Common genetic variation and human traits. N Engl J Med 360:1696–1698.CrossRefPubMedGoogle Scholar
  3. Hirschhorn JN (2009) Genomewide association studies – illuminating biologic pathways. N Engl J Med 360:1699–1701CrossRefPubMedGoogle Scholar
  4. Hunter P (2009) Reading the metabolic fine print. The application of metabolomics to diagnostics, drug research and nutrition might be integral to improved health and personalized medicine. EMBO Rep 10:20–23CrossRefPubMedGoogle Scholar
  5. Jain KK (2006a) A critical review of the royal society’s report on personalized medicine (editorial). Drug Discov Today 11:573–575CrossRefGoogle Scholar
  6. Khoury MJ, Gwinn M, Yoon PW et al (2007) The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 9:665–674CrossRefPubMedGoogle Scholar
  7. Scheuner MT, Sieverding P, Shekelle PG (2008) Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 299:1320–1334Google Scholar
  8. Vizirianakis IS (2007) Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping. Clin Pharmacokinet 46:807–824CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations